Cancer Communications

Papers
(The H4-Index of Cancer Communications is 52. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Kindlin‐1 drives early steps of breast cancer metastasis570
389
354
Treatment of Metastatic Cancer by Conferring Immunogenicity to the Apoptotic Bodies of the Primary Tumor301
Correction to “Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges”297
Nine‐fold variation of risk of advanced colorectal neoplasms according to smoking and polygenic risk score: Results from a cross‐sectional study in a large screening colonoscopy cohort266
Issue Information238
Loss of CDKN1B induces an age‐related clonal hematopoietic disorder via Notch2 activity dysregulation217
Issue Information215
Issue Information171
Defining and tracing subtypes of patient‐derived xenograft models in pancreatic ductal adenocarcinoma162
Combined local therapy and CAR‐GPC3 T‐cell therapy in advanced hepatocellular carcinoma: a proof‐of‐concept treatment strategy161
Dysregulated Proline Metabolism Exacerbates Hepatocellular Carcinoma Metastasis via EPRS1-Mediated mRNA Translation153
Single‐cell transcriptomics and epigenomics point to CD58‐CD2 interaction in controlling primary melanoma growth and immunity149
Long‐term survival outcomes and immune checkpoint inhibitor retreatment in patients with advanced cervical cancer treated with camrelizumab plus apatinib in the phase II CLAP study147
Signaling pathways in cancer‐associated fibroblasts: recent advances and future perspectives146
Current status and perspectives of esophageal cancer: a comprehensive review141
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update134
Validation of different personalized risk models of chemotherapy‐induced nausea and vomiting: results of a randomized, double‐blind, phase III trial of fosaprepitant for cancer patients treated with h132
Efficacy and safety of first‐line sintilimab plus anlotinib versus chemotherapy for metastatic non‐small cell lung cancer: a phase II, open‐label, randomized controlled trial124
Single‐cell transcriptomics provides insights into the origin and immune microenvironment of cervical precancerous lesions114
Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2‐negative breast cancer114
Comparative single‐cell analysis of esophageal cancer subtypes reveals tumor microenvironment distinctions explaining varied immunotherapy responses113
EXPRESSION OF CONCERN: Discovery of a Novel Viroid‐Like Circular RNA in Colorectal Cancer107
Partial hepatectomy versus interventional treatment in patients with hepatitis B virus‐related hepatocellular carcinoma and clinically significant portal hypertension: a randomized comparative clinica101
Neoadjuvant chemoradiotherapy with capecitabine and irinotecan guided by UGT1A1 status in patients with locally advanced rectal cancer: 5‐year update of 97
Issue Information97
Development and validation of an artificial intelligence model for predicting post‐transplant hepatocellular cancer recurrence96
Nasopharyngeal carcinoma treatment paradigm after HK0501 – a potential way forward80
p38γ and p38δ as biomarkers in the interplay of colon cancer and inflammatory bowel diseases74
A nanotherapeutic strategy to target drug‐tolerant cells and overcome EGFR tyrosine kinase inhibitor resistance in lung cancer73
Issue Information70
68
68
Impact of pre‐existing cardiometabolic diseases on metastatic cancer stage at diagnosis: a prospective multinational cohort study66
N 6 ‐methyladenosine‐regulated exosome biogenesis orchestrates an immunosuppressive pre‐metastatic niche in gastric cancer peritoneal metastas66
Oral transforming growth factor‐beta receptor 1 inhibitor vactosertib promotes osteosarcoma regression by targeting tumor proliferation and enhancing anti‐tumor immunity66
Residual circulating tumor DNA after adjuvant chemotherapy effectively predicts recurrence of stage II‐III gastric cancer66
Acquired RD3 loss regulates immune surveillance in high‐risk and therapy defying progressive neuroblastoma62
Cover Image, Volume 45, Issue 662
Novel molecular mechanisms of immune evasion in hepatocellular carcinoma: NSUN2‐mediated increase of SOAT2 RNA methylation62
Targeting IL‐17A to manage immunotherapy‐induced toxicity in melanoma61
Association of previously irradiated stable brain metastases with outcomes of atezolizumab‐treated non‐small cell lung cancer: A pooled analysis of individual patient data from three randomized trials61
Impact of small molecule‐mediated inhibition of ammonia detoxification on lung malignancies and liver metabolism60
FOXO1 or not FOXO1: that is the question60
Issue Information57
First-Line Tislelizumab Combined with Bevacizumab and CAPOX for Metastatic Gastroesophageal Adenocarcinoma with Low Programmed Death-Ligand 1 Expression56
Incidence of and survival with bone and soft tissue sarcoma: A nation‐wide study over four decades55
A strong internal promoter drives massive expression of YEATS‐domain devoid MLLT3 transcripts in HSC and most lethal AML55
Ubiquitination in cancer: mechanisms and therapeutic opportunities53
Harnessing chimeric antigen receptor macrophages against solid tumors52
Antitumoral effects of cannabis in Notch1 ‐mutated T‐cell acute lymphoblastic leukemia52
0.29380488395691